A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

  • STATUS
    Not Recruiting
  • sponsor
    Insmed
Updated on 2 August 2021
bronchiectasis

Summary

This study will investigate the efficacy, safety, and tolerability of brensocatib in the clinical management of subjects with Non-Cystic Fibrous Bronchiectasis (NCFBE).

Subjects will be randomized in a 1:1:1 ratio to 3 treatment arms to receive brensocatib 10 mg once daily (QD), brensocatib 25 mg QD, or matching placebo QD for 52 weeks.

The goals are to confirm the findings from the phase two study, INS1007-201 and, if successful, to support marketing authorizations for brensocatib for the treatment of adult patients with NCFBE.

Description

  • Condition: Non-Cystic Fibrous Bronchiectasis (NCFBE)
  • Drug: Brensocatib 
  • Clinical Trial Identifier: NCT04594369
  • Sponsor: Insmed Incorporated 

Details
Condition Pulmonary Fibrosis
Clinical Study IdentifierTX276502
SponsorInsmed
Last Modified on2 August 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note